Joseph Baisden, MD
Radiation Oncology · Princeton, WVNPI 1609816214
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Novartis at 36.9% of the total. 2025 is the largest year on record at $117, 3.6 times the $33 reported in 2019.
Across 15 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$120
- Novocure Inc.$96
- AstraZeneca$31
- Pfizer$25
- Telix Pharmaceuticals$21
- Bayer$17
- plus $16 from 1 others
What the payments were for
- Food & beverage$326100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $120 |
| Novocure Inc. | 5 | $96 |
| AstraZeneca | 1 | $31 |
| Pfizer | 1 | $25 |
| Telix Pharmaceuticals | 1 | $21 |
| Bayer | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
How this compares
$326 in reported general payments places this provider in the 55th percentile of 29 radiation oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 21 | $1,702 |
| Oxycodone Hcl | 50 | $1,356 |
| Tamsulosin Hcl | 177 | $1,250 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 14 | $1,163 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 30 | $1,015 |
| Megestrol Acetate | 13 | $688 |
| Lidocaine Hcl ViscousLidocaine Hcl | 42 | $664 |
| Ondansetron OdtOndansetron | 24 | $562 |
| Ondansetron Hcl | 24 | $561 |
| Triamcinolone Acetonide | 35 | $560 |
| Gabapentin | 33 | $559 |
| Silver Sulfadiazine | 13 | $480 |
| Levetiracetam | 14 | $303 |
| Sulfasalazine | 25 | $286 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $267 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Princeton
- John VarlottoHuntington$120K
- Gregory MerrickWheeling$21K
- David ShimmBeckley$5K
- Paul AdedoyinHuntington$3K
- Benjamin YanMorgantown$2K
- Michael GallowayElkins$1K
- Jondavid PollockWheeling$1K
- Jon-Michael StorkMorgantown$1K
- Sanjeev SharmaHuntington$1K
- Greeshma Rajeev-KumarWheeling$891
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.